Key Highlights

  • Senseonics (NASDAQ:SENS) gained 26.12% to close at USD 12.36 after lifting 2026 Revenue guidance to USD 68 million to USD 70 million. Zura Bio (NASDAQ:ZURA) bounced back 19.31% to USD 1.48.
  • Harrow, Inc. (NASDAQ:HROW) rose 15.85% to USD 31.83 on third quarter revenue of USD 99.3 million. Zentalis (NASDAQ:ZNTL) added 12.36% to USD 1.96 after beating on a USD 0.24 per share loss.
  • IRulya Therapeutics (NASDAQ:IRLA) climbed 12.15% to USD 37.88 on only 53,290 shares, with no catalyst identified in published coverage for the session.
  • Volume spanned 53,290 shares at a relative Volume of 0.68 up to 6.71 million shares, and market values ran from USD 38.53 million to USD 1.19 billion, so Liquidity and size vary widely across the five names.

Senseonics (NASDAQ:SENS): Up 26.12% on Raised Guidance and Third-Quarter Results

Senseonics, maker of the Eversense implantable continuous glucose monitoring system, finished the regular session at USD 12.36, up 26.12% from a calculated prior close of USD 9.80. Volume was 2.12 million shares at a relative volume of 2.70. The catalyst was the November 9 release, with third-quarter revenue of USD 19.6 million versus USD 8.1 million, a gross Margin near 62% and 2026 revenue guidance lifted to USD 68 million to USD 70 million from USD 62 million to USD 66 million. As general context, higher guidance resets analyst models and can draw buyers. The snapshot Market Value is USD 653.52 million, while 54,775,503 shares at USD 12.36 give about USD 677.0 million (calculated), a gap that hints at a different share basis. Cash and short-term investments were USD 126.6 million against USD 55.0 million of principal under the Hercules facility. The net loss grew to USD 32.7 million, so financing and dilution remain risks for Senseonics (NASDAQ:SENS), and nothing here suggests the move will continue.

Zura Bio (NASDAQ:ZURA): Up 19.31% on a Rebound With No New Catalyst Identified

Zura Bio closed at USD 1.48, up 19.31% from a calculated prior close of USD 1.24, the session after a roughly 76% plunge reported on a failed Phase 2 trial. The TibuSHIELD study of tibulizumab in 247 patients showed lesion count reductions of 56% and 58.1% against 52.5% on placebo after 16 weeks, and published coverage identified no separate announcement dated November 10, 2026. As general context, a stock trading beneath its cash can draw bargain buying and short covering, but these are not confirmed causes. Volume was 6.71 million shares at a relative volume of 0.71, worth about USD 9.93 million (calculated). The market value of USD 142.5 million is below reported cash of USD 187.7 million, a gap of about USD 45.2 million (calculated), yet trailing EPS is USD -1.25. A price under USD 1.00 could invite a Nasdaq minimum bid deficiency, a risk for Zura Bio (NASDAQ:ZURA), and prices can still gap.

Harrow, Inc. (NASDAQ:HROW): Up 15.85% on Third Quarter Results and Lower EBITDA Guidance

Harrow closed at USD 31.83, up 15.85% from a calculated prior close of USD 27.48, which was only 1.9% over the 52-week low of USD 26.96. The identified catalyst is the results release, with revenue of USD 99.3 million, up 39%, Net Income of USD 9.8 million and adjusted EBITDA of USD 21.2 million, although full-year adjusted EBITDA guidance dropped to above USD 40 million from USD 80 million to USD 100 million. Revenue guidance of USD 350 million to USD 365 million was reaffirmed. As general context, shares often climb when a quarter clears a low bar. The market value is USD 1.19 billion, and volume of 845.9K shares at a relative volume of 1.35 implies about USD 26.9 million traded (calculated). The price remains 42.0% under the 52-week high of USD 54.85. Cash of USD 75.3 million sits against notes payable of USD 292.7 million, so Leverage is a risk for Harrow, Inc. (NASDAQ:HROW).

Zentalis (NASDAQ:ZNTL): Up 12.36% on a Third-Quarter Loss Beat and Cash Build

Zentalis closed at USD 1.96, up 12.36% from a calculated prior close of USD 1.74. After the close on November 9, the company posted a third-quarter loss of USD 0.34 per share against a consensus loss of USD 0.58, a USD 0.24 beat. Cash, equivalents and marketable securities were USD 228.9 million at September 30, 2026, with runway guided into the first half of 2028. An integrated DENALI Part 2 topline readout is due in the first half of 2027. The snapshot market value of USD 185.08 million implies about 94.4 million shares (calculated) and equals about 81% of cash. Volume was 712,490 shares at a relative volume of 0.50, worth about USD 1.4 million (calculated), so a few trades can move the price. Risks for Zentalis (NASDAQ:ZNTL) include a negative readout, a delay on the FDA path, dilution after the August offering of 26,450,000 shares and a nine-month net loss of USD 106.5 million.

IRulya Therapeutics (NASDAQ:IRLA): Up 12.15% With No Identified Catalyst

IRulya Therapeutics, previously Quince Therapeutics, closed at USD 37.88, up 12.15% from a calculated prior close of USD 33.78. Published coverage identified no catalyst for November 10, 2026. The latest company release found, dated November 9, announced inducement grants, a routine hiring disclosure. The pipeline centres on LAM-001, an inhaled dry powder rapamycin, with Phase 2 data in bronchiolitis obliterans syndrome due in the first quarter of 2027. Volume was 53,290 shares at a relative volume of 0.68, worth about USD 2.02 million (calculated). The data conflict: the snapshot market value of USD 38.53 million implies about 1.02 million shares, while the company cited about 10,841,470 shares after a preferred conversion, and trailing EPS of USD -125.60 is unverified. Cash was USD 116 million at June 30, 2026. Thin trading means a few trades can move the price of IRulya Therapeutics (NASDAQ:IRLA), and the move does not imply further gains.

Where Things Stand

Five healthcare names headed the session, and the largest mover was Senseonics (NASDAQ:SENS) at +26.12%. The common thread is a published screener snapshot of the November 10, 2026 regular session, with most gains tied to results or a rebound. Zura Bio (NASDAQ:ZURA) had no new catalyst identified. Neither did IRulya Therapeutics (NASDAQ:IRLA). For Canadian readers following US healthcare names, large one-day moves in thinly traded stocks can reverse in the next session because a few orders can move the price, spreads are wide and buyers who chased the gain may sell. Harrow, Inc. (NASDAQ:HROW) had results. So did Zentalis (NASDAQ:ZNTL).